Trials / Completed
CompletedNCT04686136
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 596 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atogepant 60 mg | Tablets containing 60 mg of Atogepant |
Timeline
- Start date
- 2021-02-19
- Primary completion
- 2025-10-20
- Completion
- 2025-10-20
- First posted
- 2020-12-28
- Last updated
- 2025-12-18
Locations
116 sites across 14 countries: United States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04686136. Inclusion in this directory is not an endorsement.